MedTrace Logo

Positive Association of US-FLI With the Severity of CAD

NCT06541132 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2024-08-21

No results posted yet for this study

Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Conditions

  • Coronary Artery Disease of Significant Bypass Graft
  • Metabolic Dysfunction-associated Fatty Liver Disease
  • SYNTAX Score
  • Ultrasonography

Interventions

OTHER

Observational study without human intervention

Observational study without human intervention

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-04-28
Completion
2025-04-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06541132 on ClinicalTrials.gov